Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of both complex mixture generic and novel drugs.
Spotlight
Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics
DEERFIELD, Ill. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars. Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions. With this collaboration, Baxter will leverage its leading clinical development and biologic manufacturing expertise, global leadership in sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development.
Read more here.
Momenta Featured in Nature Biotechnology!
Chinese Hamster Ovary Cells Can Produce Galactose-α-1,3-Galactose Antigens on Proteins
Read more about it here.
Congratulations to Momenta Pharmaceuticals President and CEO Craig Wheeler for receiving the Ernst & Young Entrepreneur Of The YearŽ 2011 New England Award in the Biotechnology category!
Click here to see the video